MOR News and Press, MorphoSys AG From 02/24/24

2024-02-24 21:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-16 10:29:22 ET More on Novartis Novartis And MorphoSys Are A Perfect Match Novartis AG (NVS) Q4 2023 Earnings Call Transcript Novartis AG 2023 Q4 - Results - Earnings Call Presentation MorphoSys ADRs gain after definitive merger agreement with Novarti...

2024-02-14 15:20:31 ET More on Incyte Incyte Corporation (INCY) Q4 2023 Earnings Call Transcript Incyte Corporation 2023 Q4 - Results - Earnings Call Presentation Incyte: Overly Reliant On Jakafi Despite Positive Phase 2 Results For Axatilimab Incyte Q4 2023 ...

2024-02-14 03:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-07 09:52:29 ET More on MorphoSys Novartis And MorphoSys Are A Perfect Match MorphoSys: Positive Pelabresib Data Finally Unlocking Upside MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis MorphoSys drops amid speculation ...

2024-02-06 12:21:34 ET More on MorphoSys Novartis And MorphoSys Are A Perfect Match MorphoSys: Positive Pelabresib Data Finally Unlocking Upside MorphoSys: A Buying Opportunity Following Mixed Phase 3 Results In Myelofibrosis Incyte buys global rights for taf...

A look at the top 10 most actives in the United States Phunware Inc. (PHUN) rose 19.9% to $0.41 on volume of 260,182,609 shares Palantir Technologies Inc. Class A (PLTR) fell 1.8% to $16.72 on volume of 167,698,349 shares PROSHARES TRUST (SQQQ) rose 0.5% to $11.78 on volume of 155,646,888...

2024-02-06 08:00:00 ET Summary Novartis plans to acquire MorphoSys, a German biopharmaceutical company, for EUR 2.7 billion in cash. The acquisition will give Novartis access to MorphoSys' extensive oncological pipeline, including the potentially game-changing treatment option for...

2024-02-05 17:52:08 ET More on Incyte Incyte: Overly Reliant On Jakafi Despite Positive Phase 2 Results For Axatilimab Agilent, Incyte to collaborate on companion diagnostics development Why did Incyte stock go up today? Positive drug study Seeking Alpha ...

Tafasitamab sold to Incyte Novartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cash Shareholders benefit from attractive premium of 94 percent to the one-month volume weighted average price before January 25, 2024 Novar...